Jove
Visualize
Contact Us

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Vaccinations01:51

Vaccinations

Overview
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Cross-protective Efficacy Of Hpv-16/18 As04-adjuvanted Vaccine Against Cervical Infection And Precancer Caused By Non-vaccine Oncogenic Hpv Types: 4-year End-of-study Analysis Of The Randomised, Double-blind Patricia Trial.
  1. Home
  3. Cross-protective Efficacy Of Hpv-16/18 As04-adjuvanted Vaccine Against Cervical Infection And Precancer Caused By Non-vaccine Oncogenic Hpv Types: 4-year End-of-study Analysis Of The Randomised, Double-blind Patricia Trial.

Related Experiment Video

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by

Cosette M Wheeler1, Xavier Castellsagué, Suzanne M Garland

  • 1Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. cwheeler@salud.unm.edu

The Lancet. Oncology
|November 15, 2011

View abstract on PubMed

Summary
This summary is machine-generated.

More Related Videos

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

Related Experiment Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

The HPV-16/18 vaccine demonstrated cross-protective efficacy against non-vaccine oncogenic HPV types, including HPV-33, HPV-31, HPV-45, and HPV-51. This finding supports broader protection beyond vaccine-targeted HPV types in women.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • The PApilloma TRIal against Cancer In young Adults (PATRICIA) evaluated the HPV-16/18 AS04-adjuvanted vaccine's efficacy.
  • This study focused on the vaccine's effectiveness against oncogenic human papillomavirus (HPV) types not included in the vaccine formulation.

Purpose of the Study:

  • To assess the cross-protective efficacy of the HPV-16/18 vaccine against non-vaccine oncogenic HPV types.
  • To analyze vaccine effectiveness in different cohorts representing diverse female populations.

Main Methods:

  • A double-blind, randomized controlled trial involving healthy women aged 15-25 years.
  • Participants received either the HPV-16/18 vaccine or a control hepatitis A vaccine.
  • Efficacy was evaluated against persistent infection and cervical intraepithelial neoplasia (CIN2+ and CIN3+) associated with 12 non-vaccine HPV types.

Main Results:

  • The HPV-16/18 vaccine showed significant efficacy against persistent infection and CIN2+ for HPV-33, HPV-31, HPV-45, and HPV-51.
  • In conservative analyses, efficacy was observed for HPV-33 and HPV-31 against CIN2+.
  • Efficacy against CIN2+ for a composite of 12 non-vaccine HPV types ranged from 34.2% to 56.2%, and for CIN3+ from 47.5% to 91.4% across cohorts.

Conclusions:

  • The HPV-16/18 vaccine provides cross-protective benefits against specific non-vaccine oncogenic HPV types.
  • These findings highlight the vaccine's potential to offer broader protection against HPV-related cervical disease in various populations.